<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C6FEE9DF-4071-4ACE-B254-C6850BA7FD8F"><gtr:id>C6FEE9DF-4071-4ACE-B254-C6850BA7FD8F</gtr:id><gtr:name>Occams Resources LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/40D8250C-C708-4AD7-B244-058E48DD3B31"><gtr:id>40D8250C-C708-4AD7-B244-058E48DD3B31</gtr:id><gtr:name>Peter MacCallum Cancer Centre</gtr:name><gtr:address><gtr:line1>Smorgon Family Bldg</gtr:line1><gtr:line2>St Andrew's place</gtr:line2><gtr:line4>Melbourne</gtr:line4><gtr:line5>VIC, 3002</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D2A7E780-D923-4D61-B58E-3E467D303CA0"><gtr:id>D2A7E780-D923-4D61-B58E-3E467D303CA0</gtr:id><gtr:name>University of Adelaide</gtr:name><gtr:address><gtr:line1>Main Building</gtr:line1><gtr:line4>Adelaide</gtr:line4><gtr:line5>SA 5005</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C6FEE9DF-4071-4ACE-B254-C6850BA7FD8F"><gtr:id>C6FEE9DF-4071-4ACE-B254-C6850BA7FD8F</gtr:id><gtr:name>Occams Resources LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/40D8250C-C708-4AD7-B244-058E48DD3B31"><gtr:id>40D8250C-C708-4AD7-B244-058E48DD3B31</gtr:id><gtr:name>Peter MacCallum Cancer Centre</gtr:name><gtr:address><gtr:line1>Smorgon Family Bldg</gtr:line1><gtr:line2>St Andrew's place</gtr:line2><gtr:line4>Melbourne</gtr:line4><gtr:line5>VIC, 3002</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D2A7E780-D923-4D61-B58E-3E467D303CA0"><gtr:id>D2A7E780-D923-4D61-B58E-3E467D303CA0</gtr:id><gtr:name>University of Adelaide</gtr:name><gtr:address><gtr:line1>Main Building</gtr:line1><gtr:line4>Adelaide</gtr:line4><gtr:line5>SA 5005</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/660D4EDC-FEB0-4F4D-8B22-2F516712C7BA"><gtr:id>660D4EDC-FEB0-4F4D-8B22-2F516712C7BA</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Underwood</gtr:surname><gtr:orcidId>0000-0001-9455-2188</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002565"><gtr:id>3B202617-5402-450A-89EF-EE0B4498BF84</gtr:id><gtr:title>Exploring stromal-epithelial interactions in oesophageal cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002565</gtr:grantReference><gtr:abstractText>Cancer of the oesophagus (gullet) is becoming more common in the UK. Despite best current treatments the likelihood of cure is still very poor. The relationship between cells lining the oesophagus and the cells in the supporting layer beneath is fundamental to the development of oesophageal cancer. We make use of a specially developed model system to better understand this relationship with the aim of identifying new molecules as targets for cancer prevention and treatment. Our research uses human cells taken from biopsies of the oesophagus to grow a model oesophagus in the laboratory. Using this system we can determine the interaction between different cell types and the relative contribution that they make to cancer progression. Our overall aim is to understand the differences between cells in the supporting layer of the oesophagus at different stages of cancer growth and use these differences to design new ways of detecting and treating oesophageal cancer before it spreads.</gtr:abstractText><gtr:technicalSummary>Objectives: This proposal describes an innovative programme of work to establish the importance of stromal-epithelial interactions in human oesophageal cancer.

Background: Carcinoma of the oesophagus is the 6th leading cause of cancer death with a 5-year survival of less than 15%. It is the most rapidly increasing cancer in the UK and in December 2008 the Chief Medical Officer for England called for increased research into its causes. Adenocarcinoma of the oesophagus is associated with the finding of a pre-malignant columnar metaplasia in the distal oesophagus - Barrett?s oesophagus (BE). Recent evidence demonstrates that gene changes in the oesophageal stroma can be independent of changes in the epithelium, and are important in Barrett?s carcinogenesis.

Methods: This project makes use of a novel organotypic model of the oesophagus that allows molecular genetic manipulation of both the epithelial and stromal cellular components in a physiological ex-vivo setting. We will use human tissue from endoscopic biopsies and oesophageal resections, taking both a candidate gene and genome wide approach with three research aims:

1. To build on our preliminary data to establish the role of periostin in oesophageal carcinoma invasion.
2. To define the contribution of other stromal signals to the maintenance and progression of oesophageal carcinoma.
3. To analyse the molecular events required for fibroblast activation in the oesophagus.

Outcomes: This project will lead to the discovery of novel diagnostic and prognostic biomarkers, and the potential for the rational development of new interventions and therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2016-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1129004</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Adelaide</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Paul Drew</gtr:description><gtr:id>BD4467DE-808C-4107-A3B5-8007E63EE690</gtr:id><gtr:impact>Manuscript in preparation.</gtr:impact><gtr:outcomeId>R4ro7FLDnmo-1</gtr:outcomeId><gtr:partnerContribution>As above.</gtr:partnerContribution><gtr:piContribution>Full collaboration between active research labs including intellectual property, cell lines and tissue samples, reagents and techniques.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Peter MacCallum Cancer Centre</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Nick Clemons</gtr:description><gtr:id>84497E65-EA47-4EDE-B332-9C9F89996FCE</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>ZvefMxwjAFo-1</gtr:outcomeId><gtr:partnerContribution>Full collaboration.</gtr:partnerContribution><gtr:piContribution>Full laboratory collaboration including grant writing, experimental design, conduct, result sharing and write-up.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Cancer Cell Unit</gtr:department><gtr:description>OCCAMS</gtr:description><gtr:id>D28A5E9A-554F-4839-97A4-4E78BC8BC410</gtr:id><gtr:impact>Weaver, Jamie M.J., Ross-Innes, Caryn S., Shannon, Nicholas, Lynch, Andy G., Forshew, Tim, Barbera, Mariagnese, Murtaza, Muhammed, Ong, Chin-Ann J., Lao-Sirieix, Pierre, Dunning, Mark J., Smith, Laura, Smith, Mike L., Anderson, Charlotte L., Carvalho, Benilton, O'Donovan, Maria, Underwood, Timothy J., May, Andrew P., Grehan, Nicola, Hardwick, Richard, Davies, Jim, Oloumi, Arusha, Aparicio, Sam, Caldas, Carlos, Eldridge, Matthew D., Edwards, Paul A.W., Rosenfeld, Nitzan, Tavar&amp;eacute;, Simon and Fitzgerald, Rebecca C. (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics, 46, (8), 837-843. (doi:10.1038/ng.3013 ). (PMID:24952744).

THE TIMING OF ONCOGENIC EVENTS IN THE EVOLUTION OF THE OESOPHAGEAL ADENOCARCINOMA GENOME AND IMPLICATIONS FOR CLINICAL DIAGNOSTICS
J. Weaver 1,*, C. Ross-Innes 2, N. Shannon 3, A. Lynch 3, M. Murtaza 3, T. Forshew 3, M. Dunning 3, T. Underwood 4, R. Hardwick 5, M. Eldridge 3, P. Edwards 1, N. Rosenfeld 3, S. Tavare 3, R. Fitzgerald 2 on behalf of The Occams and ICGC Oesophageal Adenocarcinoma consortium
1Department of Pathology, 2Hutchison-MRC, 3CRUK Cambridge institute, Cambridge, 4Cancer sciences division, Southampton, 5Addenbrooke's Hospital, Cambridge University NHS Foundation Trust , Cambridge, United Kingdom
 
Does this abstract contain original data?: Yes
Will this abstract be published/presented prior to June 2014?: Yes
Abstract published in/presented at: DDW 20 14, APAM 2014
Preferred presentation type: Oral or poster
Introduction: A series of clonal expansions are thought to underlie the progression of Barrett's oesophagus (BE) to oesophageal adenocarcinoma (OAC). Each expansion carries with it somatic driver mutation(s) fixing it within a larger population and therefore increasing the likelihood of acquiring a second mutation. However, the precise order in which somatic variants occur remains unknown.
Methods: We performed whole genome sequencing in 25 cases of OAC and 3 matched cases of BE. Findings were validated in a larger cohort of OACs (n=90), metaplastic never-dysplastic BE (NDBE, n= 66 with a median follow-up of 58 months) and high-grade dysplasia (n = 43) using amplicon resequencing. Mutational signatures and gene-centric somatic mutations were determined using an in-house pipeline incorporating standard statistical methods and the publically available EMu pipeline.
Results: There were 7 distinct mutational signatures present in both early (BE) and late disease (OAC). Fifteen genes were determined to be potential novel drivers of OAC development. Surprisingly in 53% of NDBE tissue samples we identified clonal expansion of cells (&amp;gt;10% mutant fraction) harbouring mutations in one or more of 13/15 of these putative driver genes. No difference in the frequency of mutation of these genes was observed between any of the disease stages studied. TP53 mutations clearly delineate between HGD/OAC and benign NDBE (p&amp;lt;0.001). Whilst SMAD4 mutations are only observed in OAC (p&amp;lt;0.001) demonstrating for the first time a clear genetic difference between the two.
Conclusion: Mutagenic processes active in OAC are also active in the earliest stages of BE. Recurrent driver mutations identified in cancer may be acquired very early in the disease and may provide little or no progression advantage. Molecular diagnostic approaches must account for this.
 
Disclosure of Interest: None Declared</gtr:impact><gtr:outcomeId>HtkhHYBk5f4-1</gtr:outcomeId><gtr:partnerContribution>Sequencing and bioinformatic analysis of sequence data.</gtr:partnerContribution><gtr:piContribution>A UK multi-center collaboration to perform whole genome sequencing of 500 oesophageal cancers and matched normal tissue. We provided approximately 50% of samples for the pilot study that secured full funding from CRUK for the complete programme.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Blizard Institute</gtr:department><gtr:description>Janusz</gtr:description><gtr:id>9472FD03-8852-497A-8D43-4BA49B7126FC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>cZTd7n8guAC-1</gtr:outcomeId><gtr:partnerContribution>Genomic profiling of germ-line DNA to find predictors of oesophageal cancer susceptibility.</gtr:partnerContribution><gtr:piContribution>Provision of patient samples and associated meta-data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Occams Resources LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>OCCAMS</gtr:description><gtr:id>456AA7DE-F7A4-4A7C-82CD-3EAA84657B8E</gtr:id><gtr:impact>Weaver, Jamie M.J., Ross-Innes, Caryn S., Shannon, Nicholas, Lynch, Andy G., Forshew, Tim, Barbera, Mariagnese, Murtaza, Muhammed, Ong, Chin-Ann J., Lao-Sirieix, Pierre, Dunning, Mark J., Smith, Laura, Smith, Mike L., Anderson, Charlotte L., Carvalho, Benilton, O'Donovan, Maria, Underwood, Timothy J., May, Andrew P., Grehan, Nicola, Hardwick, Richard, Davies, Jim, Oloumi, Arusha, Aparicio, Sam, Caldas, Carlos, Eldridge, Matthew D., Edwards, Paul A.W., Rosenfeld, Nitzan, Tavar&amp;eacute;, Simon and Fitzgerald, Rebecca C. (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics, 46, (8), 837-843. (doi:10.1038/ng.3013 ). (PMID:24952744).

THE TIMING OF ONCOGENIC EVENTS IN THE EVOLUTION OF THE OESOPHAGEAL ADENOCARCINOMA GENOME AND IMPLICATIONS FOR CLINICAL DIAGNOSTICS
J. Weaver 1,*, C. Ross-Innes 2, N. Shannon 3, A. Lynch 3, M. Murtaza 3, T. Forshew 3, M. Dunning 3, T. Underwood 4, R. Hardwick 5, M. Eldridge 3, P. Edwards 1, N. Rosenfeld 3, S. Tavare 3, R. Fitzgerald 2 on behalf of The Occams and ICGC Oesophageal Adenocarcinoma consortium
1Department of Pathology, 2Hutchison-MRC, 3CRUK Cambridge institute, Cambridge, 4Cancer sciences division, Southampton, 5Addenbrooke's Hospital, Cambridge University NHS Foundation Trust , Cambridge, United Kingdom
 
Does this abstract contain original data?: Yes
Will this abstract be published/presented prior to June 2014?: Yes
Abstract published in/presented at: DDW 20 14, APAM 2014
Preferred presentation type: Oral or poster
Introduction: A series of clonal expansions are thought to underlie the progression of Barrett's oesophagus (BE) to oesophageal adenocarcinoma (OAC). Each expansion carries with it somatic driver mutation(s) fixing it within a larger population and therefore increasing the likelihood of acquiring a second mutation. However, the precise order in which somatic variants occur remains unknown.
Methods: We performed whole genome sequencing in 25 cases of OAC and 3 matched cases of BE. Findings were validated in a larger cohort of OACs (n=90), metaplastic never-dysplastic BE (NDBE, n= 66 with a median follow-up of 58 months) and high-grade dysplasia (n = 43) using amplicon resequencing. Mutational signatures and gene-centric somatic mutations were determined using an in-house pipeline incorporating standard statistical methods and the publically available EMu pipeline.
Results: There were 7 distinct mutational signatures present in both early (BE) and late disease (OAC). Fifteen genes were determined to be potential novel drivers of OAC development. Surprisingly in 53% of NDBE tissue samples we identified clonal expansion of cells (&amp;gt;10% mutant fraction) harbouring mutations in one or more of 13/15 of these putative driver genes. No difference in the frequency of mutation of these genes was observed between any of the disease stages studied. TP53 mutations clearly delineate between HGD/OAC and benign NDBE (p&amp;lt;0.001). Whilst SMAD4 mutations are only observed in OAC (p&amp;lt;0.001) demonstrating for the first time a clear genetic difference between the two.
Conclusion: Mutagenic processes active in OAC are also active in the earliest stages of BE. Recurrent driver mutations identified in cancer may be acquired very early in the disease and may provide little or no progression advantage. Molecular diagnostic approaches must account for this.
 
Disclosure of Interest: None Declared</gtr:impact><gtr:outcomeId>HtkhHYBk5f4-2</gtr:outcomeId><gtr:partnerContribution>Sequencing and bioinformatic analysis of sequence data.</gtr:partnerContribution><gtr:piContribution>A UK multi-center collaboration to perform whole genome sequencing of 500 oesophageal cancers and matched normal tissue. We provided approximately 50% of samples for the pilot study that secured full funding from CRUK for the complete programme.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Tumour Biology</gtr:department><gtr:description>Stuart McDonald</gtr:description><gtr:id>309CFC96-E945-44E4-9AAB-9BD1F37894A5</gtr:id><gtr:impact>A manuscript: &amp;quot;The stem cell organization, and the proliferative and gene expression profile of Barrett's epithelium, indicates an origin from gastric glands&amp;quot; has been submitted to Gastroenterology</gtr:impact><gtr:outcomeId>hdx2tvoDpjW-1</gtr:outcomeId><gtr:partnerContribution>Dissection of the clonal origins of Barrett's oesophagus.</gtr:partnerContribution><gtr:piContribution>Intellectual and material collaboration. We have provided fresh-frozen samples of Barrett's oesophagus made possible by the MRC funding of a research nurse as part of my Clin Sci award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radio interview BBC Solent</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C4CF1665-217B-4948-8E7C-7F5D75BB540F</gtr:id><gtr:impact>A number of radio interviews running up to the London Marathon. Raised public awareness of Oesophageal cancer and heartburn.

N/A</gtr:impact><gtr:outcomeId>tWeeqeNVq45</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Cancer Marathon Project</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9403D098-FF8D-4860-8806-B72FBFD4F69D</gtr:id><gtr:impact>A large scale engagement and awareness initiative about oesophageal cancer. Multiple newspaper reports, quotes and radio appearances, including:

http://www.bbc.co.uk/news/health-22940088

http://www.independent.co.uk/life-style/health-and-families/health-news/persisted-heartburn-sufferers-urged-to-visit-doctor-to-rule-out-cancer-8662677.html

http://www.telegraph.co.uk/health/healthnews/10125641/Persistent-heartburn-sufferers-could-have-oesophageal-cancer-experts-warn.html

http://www.dailymail.co.uk/health/article-2343560/Obesity-fuels-rise-throat-cancer-men-Form-deadliest-diagnosed-late.html

http://www.southampton.ac.uk/mediacentre/news/2013/jun/13_116.shtml




Asked to provide further media work for CRUK</gtr:impact><gtr:outcomeId>Yat97hNhTWB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://thecancermarathon.org/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HCAS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD0A0959-4474-4CFD-AA8C-9A7C1FC2358A</gtr:id><gtr:outcomeId>bbvxR1VFFdj</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Upper GI Clinical Studies OG subgroup</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86108C99-8B73-4994-AC9A-73B8943BEED1</gtr:id><gtr:impact>The NCRI Oesophago-gastric Subgroup meets to determine the future priorities of clinical research into oesophago-gastric cancer in the United Kingdom. I am a member of this advisory panel.</gtr:impact><gtr:outcomeId>AFEzMqwwWKY</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Be Clear on Cancer Oesophageal cancer campaign</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A3087C06-1D53-4423-B481-7ABDA47DB7DC</gtr:id><gtr:impact>The regional pilot programme for Be Clear on Cancer (oesophageal cancer) in the North East of England showed a 50% increase in the diagnosis of gastric cancer and 40% increase in the diagnosis of oesophageal cancer. It will become a National campaign in Jan 2015.</gtr:impact><gtr:outcomeId>Qh7jqop8AAd</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.nhs.uk/be-clear-on-cancer/oesophagogastric-cancer</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Background: Pre-clinical data demonstrate that aspirin inhibits tumour growth and prevents metastases. Meta-analyses of individual patient data from randomized trials evaluating cardiovascular (CV) effects of aspirin show reduced metastases and cancer deaths for those on aspirin. Toxicity concerns have limited aspirin use as a primary anti-cancer prevention agent. In the adjuvant setting, the risk:benefit ratio differs, with higher morbidity and mortality from recurrence potentially outweighing risks. Aspirin, an inexpensive drug with a potential therapeutic role in several common cancers, could have a large impact on the global cancer burden. The Add-Aspirin trial investigates if aspirin use after curative treatment for non-metastatic solid tumours prevents recurrence and prolongs survival. Methods: Add-Aspirin is a double blind, placebo-controlled, multicentre, international trial. Eligible participants (n=9,920) from the UK and India will have had potentially curative treatment for non-metastatic cancer. There are 4 separate tumour cohorts - breast (BC), colorectal (CRC), gastro-oesophageal (GOC) and prostate cancer (PC). Following an 8 week active run-in period of aspirin 100mg daily to assess adherence and tolerability, participants are randomised to aspirin 100mg, 300mg or placebo daily for &amp;gt; 5 years. Each tumour specific cohort is individually powered and has a separate disease-specific primary outcome measure: BC (n = 3,100) invasive disease-free survival (DFS); CRC (n = 2,600) DFS; GOC (n = 2,100) overall survival (OS); and PC (n = 2,120) biochemical recurrence-free survival. Secondary outcome measures include adherence, toxicity and CV events. OS across the 4 cohorts is a co-primary outcome measure. Sub-studies include assessment of thromboxane B2 for compliance and methodological work to assess the utility of long-term passive follow up. Blood/tissue specimens collected at enrolment will allow tumour-specific mutations to be used as stratification factors. Recruitment will commence by May 2014. Funder CRUK; Sponsor University College UK. Clinical trial information: 2013-004398-28.</gtr:description><gtr:id>00664592-AE43-43B0-AB59-5167622CF95F</gtr:id><gtr:impact>Background: Pre-clinical data demonstrate that aspirin inhibits tumour growth and prevents metastases. Meta-analyses of individual patient data from randomized trials evaluating cardiovascular (CV) effects of aspirin show reduced metastases and cancer deaths for those on aspirin. Toxicity concerns have limited aspirin use as a primary anti-cancer prevention agent. In the adjuvant setting, the risk:benefit ratio differs, with higher morbidity and mortality from recurrence potentially outweighing risks. Aspirin, an inexpensive drug with a potential therapeutic role in several common cancers, could have a large impact on the global cancer burden. The Add-Aspirin trial investigates if aspirin use after curative treatment for non-metastatic solid tumours prevents recurrence and prolongs survival. Methods: Add-Aspirin is a double blind, placebo-controlled, multicentre, international trial. Eligible participants (n=9,920) from the UK and India will have had potentially curative treatment for non-metastatic cancer. There are 4 separate tumour cohorts - breast (BC), colorectal (CRC), gastro-oesophageal (GOC) and prostate cancer (PC). Following an 8 week active run-in period of aspirin 100mg daily to assess adherence and tolerability, participants are randomised to aspirin 100mg, 300mg or placebo daily for &amp;gt; 5 years. Each tumour specific cohort is individually powered and has a separate disease-specific primary outcome measure: BC (n = 3,100) invasive disease-free survival (DFS); CRC (n = 2,600) DFS; GOC (n = 2,100) overall survival (OS); and PC (n = 2,120) biochemical recurrence-free survival. Secondary outcome measures include adherence, toxicity and CV events. OS across the 4 cohorts is a co-primary outcome measure. Sub-studies include assessment of thromboxane B2 for compliance and methodological work to assess the utility of long-term passive follow up. Blood/tissue specimens collected at enrolment will allow tumour-specific mutations to be used as stratification factors. Recruitment will commence by May 2014. Funder CRUK; Sponsor University College UK. Clinical trial information: 2013-004398-28.</gtr:impact><gtr:outcomeId>5459e367f21393.73306902</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Add-Aspirin trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new, invasive oesophageal cancer cell line. This has been verified by SNP 6.0 array interrogation and compared with the original tumour and germ-line DNA.</gtr:description><gtr:id>91FD1977-6F51-4BC0-8462-9DB8B169E364</gtr:id><gtr:impact>Presented at the biannual International Society for Diseases on the Oesophagus World Congress in Vancouver Canada: DEVELOPING MODEL SYSTEMS TO UNDERSTAND THE FUNCTIONAL AND CLINICAL SIGNIFICANCE OF SOMATIC GENETIC VARIATIONS IN OESOPHAGEAL CANCER
Timothy Underwood, United Kingdom</gtr:impact><gtr:outcomeId>etJicGhzg8f</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MFD1</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://www.isde.net/2014WorldCongress_AbstractSessions</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Multiple primary fibroblast isolates from normal oesophagus and matched tumour.</gtr:description><gtr:id>1841A018-0743-435C-A148-1C8FE19FB8E3</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>ZgJJ27bNyoh</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Fibroblasts</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collection of oesophageal tumours with matched Barrett's, normal oesophagus and stomach samples. Blood for germ-line DNA also stored.</gtr:description><gtr:id>4A6E5924-48C7-4EFA-B5DA-16881B5A1673</gtr:id><gtr:impact>OCCAMS/ICGC project to sequence the oesophageal cancer genome.</gtr:impact><gtr:outcomeId>mHy1qt6d3iE</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Southampton tissue bank</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>721B5450-C6D8-4444-B2F8-F96F99AA07AF</gtr:id><gtr:title>Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f56610cbacdb556d31aee4d54a5b70ae"><gtr:id>f56610cbacdb556d31aee4d54a5b70ae</gtr:id><gtr:otherNames>Underwood TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5459dbfb2983f7.64172578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88A40B8B-4319-4036-A10D-EE78C947FAC4</gtr:id><gtr:title>Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3330f9ef60bad41cfe1f65c9beaae326"><gtr:id>3330f9ef60bad41cfe1f65c9beaae326</gtr:id><gtr:otherNames>Ross-Innes CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56cef3c0c061b6.52781373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8FAA806-0805-4B22-8C6E-059054515743</gtr:id><gtr:title>Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02e3dfc5e9c4b1e9c71c358c531191da"><gtr:id>02e3dfc5e9c4b1e9c71c358c531191da</gtr:id><gtr:otherNames>Hanley CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>5a72ecf5a3d301.28408331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>816036E0-AE5B-44B3-90A6-FB64F0165BF3</gtr:id><gtr:title>Bailey &amp;amp; Love's Short Practice of Surgery, 26th edition</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5d4d008b440663a41c132e03f71f2e4"><gtr:id>f5d4d008b440663a41c132e03f71f2e4</gtr:id><gtr:otherNames>Primrose JN &amp; Underwood TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-1444121278</gtr:isbn><gtr:outcomeId>MxDTP42PiLr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA8788D1-E8E7-43B1-82DF-BB151D2D52FF</gtr:id><gtr:title>Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3abe9dbc514c367d083846ea48d16b70"><gtr:id>3abe9dbc514c367d083846ea48d16b70</gtr:id><gtr:otherNames>McCormick Matthews LH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cef3c1065164.65997251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BBE5602-1167-497B-81F8-FD04FEA2A623</gtr:id><gtr:title>Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression.</gtr:title><gtr:parentPublicationTitle>Aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34b2c9f682b805630819ee3816486679"><gtr:id>34b2c9f682b805630819ee3816486679</gtr:id><gtr:otherNames>Bhome R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1945-4589</gtr:issn><gtr:outcomeId>5a72ecf5d90a66.11408134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF9718C1-4A5A-499C-8A63-B1060ABC696A</gtr:id><gtr:title>C-reactive protein 2&amp;nbsp;days after laparoscopic gastric bypass surgery reliably indicates leaks and moderately predicts morbidity.</gtr:title><gtr:parentPublicationTitle>Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1091-255X</gtr:issn><gtr:outcomeId>doi_12931_012_2082_4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95753E1C-C8D7-498E-9BF2-EB61AE70C330</gtr:id><gtr:title>A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7951f7b60bef40d7001e264e5a9f3512"><gtr:id>7951f7b60bef40d7001e264e5a9f3512</gtr:id><gtr:otherNames>Noorani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>5a72ecf561edf5.40553081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>958F67CB-632E-43A1-AC44-679F2E345263</gtr:id><gtr:title>Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer.</gtr:title><gtr:parentPublicationTitle>Annals of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc041ca56462f5476da1dca0e088ed90"><gtr:id>fc041ca56462f5476da1dca0e088ed90</gtr:id><gtr:otherNames>Dilworth MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-4932</gtr:issn><gtr:outcomeId>5a72eb3e90a631.66452961</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F9734E4-BAC6-4F7F-8397-D1137CFFB60D</gtr:id><gtr:title>Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>5459dbfacdc895.66686836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52BE4158-69A6-4334-BD6E-91580D2C9039</gtr:id><gtr:title>Fibroblasts derived from oesophageal adenocarcinoma differ in DNA methylation profile from normal oesophageal fibroblasts.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e6bc991e4a601e3505b421420837d"><gtr:id>189e6bc991e4a601e3505b421420837d</gtr:id><gtr:otherNames>Smith E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a72ecf588b514.13544697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B789EED5-2AE1-4CF7-BD08-BB84501FED30</gtr:id><gtr:title>The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e326e4facb0b289c28f9f58f9d037a76"><gtr:id>e326e4facb0b289c28f9f58f9d037a76</gtr:id><gtr:otherNames>Lavery DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5459dd7394a098.32563346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DE8B19B-8102-454D-B97F-1381BFB5CE9A</gtr:id><gtr:title>Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb144b1d57330ab7005a5f969c515ccb"><gtr:id>fb144b1d57330ab7005a5f969c515ccb</gtr:id><gtr:otherNames>Matthews LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cef3c097de40.48599001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D287DA4-AF5B-4E2C-9837-682E42A5D277</gtr:id><gtr:title>The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer.</gtr:title><gtr:parentPublicationTitle>Medical oncology (Northwood, London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1357-0560</gtr:issn><gtr:outcomeId>doi_12931_013_0596_6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E395F62-7511-45AA-BEB7-FC64E472B3C1</gtr:id><gtr:title>Risk assessment using a novel score to predict anastomotic leak and major complications after oesophageal resection.</gtr:title><gtr:parentPublicationTitle>Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1091-255X</gtr:issn><gtr:outcomeId>pm_12931_21_22419007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E14E3FD-4C3A-44ED-A44A-379BE204A151</gtr:id><gtr:title>A prospective comparison of totally minimally invasive versus open Ivor Lewis esophagectomy.</gtr:title><gtr:parentPublicationTitle>Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1120-8694</gtr:issn><gtr:outcomeId>doi_12931_12_01356_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>210FA9CD-BF43-47DC-AF48-18E9FF8A2D28</gtr:id><gtr:title>The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.</gtr:title><gtr:parentPublicationTitle>Journal of surgical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73e11d9710af23998a9983c39e521304"><gtr:id>73e11d9710af23998a9983c39e521304</gtr:id><gtr:otherNames>Curtis NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-4790</gtr:issn><gtr:outcomeId>Zr1aTbvVb7r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1F0BED8-A4FD-4FE4-9D8B-26650784E7B6</gtr:id><gtr:title>The Development, Application and Analysis of an Enhanced Recovery Programme for Major Oesophagogastric Resection.</gtr:title><gtr:parentPublicationTitle>Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f56610cbacdb556d31aee4d54a5b70ae"><gtr:id>f56610cbacdb556d31aee4d54a5b70ae</gtr:id><gtr:otherNames>Underwood TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1091-255X</gtr:issn><gtr:outcomeId>58946d44cfcf41.51044011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF0DFE64-F385-442D-A445-252071D2BACE</gtr:id><gtr:title>Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis.</gtr:title><gtr:parentPublicationTitle>Aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5c5431d1c8749df431cb44dc8c46368"><gtr:id>d5c5431d1c8749df431cb44dc8c46368</gtr:id><gtr:otherNames>Mellone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-4589</gtr:issn><gtr:outcomeId>58946d44ab1f83.90132203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3723988-4776-40C6-8508-AA0391CE722C</gtr:id><gtr:title>Chronic gastric ulceration: a novel manifestation of IgG4-related disease?</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfba00c760f3169db7535c757f239436"><gtr:id>bfba00c760f3169db7535c757f239436</gtr:id><gtr:otherNames>Bateman AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>doi_12931_011_200565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6526F96-B290-4482-BCFB-D105BAB0FC81</gtr:id><gtr:title>Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/928918b304e09bf8e9e6cdc356da3139"><gtr:id>928918b304e09bf8e9e6cdc356da3139</gtr:id><gtr:otherNames>Garcia E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>583c42285f8646.31870119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ED195F4-C6B1-4ED4-8FF1-598CA80079A8</gtr:id><gtr:title>Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>5a2fd8dea5ce90.02142571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89826B9B-C41D-4E42-AD30-47D63B1F5756</gtr:id><gtr:title>Core information set for oesophageal cancer surgery.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71b942a37f9c0bcb7e132dd63e830003"><gtr:id>71b942a37f9c0bcb7e132dd63e830003</gtr:id><gtr:otherNames>Blazeby JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>56cef3c1374685.65818757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>689D7A5F-19CF-4775-ADA8-A3E3FE244E11</gtr:id><gtr:title>Corrigendum: Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c990b17f71c785511ed528a0f5f3974b"><gtr:id>c990b17f71c785511ed528a0f5f3974b</gtr:id><gtr:otherNames>Secrier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58946d44f0c268.60223279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>417E7F03-50AB-4588-8D8F-0BA1B29BB8BE</gtr:id><gtr:title>Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7325399ebb0fd10978aa8aea2e5436ca"><gtr:id>7325399ebb0fd10978aa8aea2e5436ca</gtr:id><gtr:otherNames>Palles C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56cef3c1720127.76449027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B23BDEE2-CE1E-4C95-A4D4-585AA97CB654</gtr:id><gtr:title>Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8738dc05084caf4114839faa17ad4a1"><gtr:id>a8738dc05084caf4114839faa17ad4a1</gtr:id><gtr:otherNames>Noble F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>583c42280b4f63.46369238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F4EA246-9AD4-4262-8669-5612925DF535</gtr:id><gtr:title>A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02e3dfc5e9c4b1e9c71c358c531191da"><gtr:id>02e3dfc5e9c4b1e9c71c358c531191da</gtr:id><gtr:otherNames>Hanley CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56cef5ce320559.86987597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6907341-D7DC-4DB4-9F87-FB17EB8DE04B</gtr:id><gtr:title>Strategies to improve outcomes in esophageal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69c6b24b0bfbb0cdc1781a2782938b08"><gtr:id>69c6b24b0bfbb0cdc1781a2782938b08</gtr:id><gtr:otherNames>Cowie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5459dd57297e17.16239187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>069DD5B8-052B-4F84-80A8-77545B27BB8E</gtr:id><gtr:title>Correlation of cancer-associated fibroblasts with tumour cell invasion and chemoresistance in oesophageal adenocarcinoma</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4d522e570384bb31e07c84d7a03b790"><gtr:id>e4d522e570384bb31e07c84d7a03b790</gtr:id><gtr:otherNames>White M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5459df7340f3c1.22538444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14357DF9-109A-44E5-9693-F18B9A198CC2</gtr:id><gtr:title>Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/374f58aed2c059b62f2efd7a5fea2b87"><gtr:id>374f58aed2c059b62f2efd7a5fea2b87</gtr:id><gtr:otherNames>Weaver JMJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5459dbfb00e008.73050591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38D26BED-FFC3-48F1-85A5-1E36637B3CA5</gtr:id><gtr:title>Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c990b17f71c785511ed528a0f5f3974b"><gtr:id>c990b17f71c785511ed528a0f5f3974b</gtr:id><gtr:otherNames>Secrier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>583c422838c156.22511532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A285B5E9-B355-4ED8-8914-1220D403881F</gtr:id><gtr:title>Androgen Receptor and Androgen-Responsive Gene FKBP5 Are Independent Prognostic Indicators for Esophageal Adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Digestive diseases and sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/189e6bc991e4a601e3505b421420837d"><gtr:id>189e6bc991e4a601e3505b421420837d</gtr:id><gtr:otherNames>Smith E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-2116</gtr:issn><gtr:outcomeId>56cef642bb3675.23229036</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002565</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>